Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, December 01 2022 - 11:00
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
DUBLIN, Dec. 1, 2022 /PRNewswire-AsiaNet/ --

ERS Genomics Limited ('ERS') is pleased to announce a new license agreement 
with Cosmo Bio. This is a non-exclusive license agreement granting Japan's 
Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio.

ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for 
gene-editing, provides access to the foundational CRISPR/Cas9 intellectual 
property. Over 100 patents are held worldwide.

Eric Rhodes, CEO at ERS had the following statement: "CRISPR/Cas9 is a powerful 
genome engineering tool that has revolutionized biotechnology. At ERS we are 
committed to making our technology accessible and available. We are pleased to 
support Cosmo Bio, a leader in high performance research biotools, in their 
ongoing development with this license agreement."

Cosmo Bio's mission is to provide the latest information on technological 
advancements and products from trusted manufacturers for establishments 
involved in biology, such as educational organizations, research institutions, 
and inspection agencies worldwide.

Cosmo Bio is the latest licensee for ERS Genomics in Japan.  Speaking in 
reference to ERS'  presence in Japan, Eric further commented:

"Japan is one of the world's leading pharma and medtech markets and sets global 
benchmarks in terms of innovation and delivery. The licenses we issue in Japan 
are clear indicators to us that accelerated growth and accompanying 
opportunities in the life science sector will continue in this region for the 
foreseeable future."    

Financial details of the agreement are not disclosed.

Media contact: Dara O'Donnell ERS Genomics Tel: + 353-1-539 0083
ERS contact: Yasuto Ando, 

About ERS Genomics 
Freedom to operate with CRISPR/Cas9 technology begins with a license to the 
foundational CVC patents available from ERS Genomics. ERS provides access to 
the CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. 
Non-exclusive licenses are available for research and sale of products and 
services across multiple fields including: research tools, kits, reagents; 
discovery of novel targets for therapeutic intervention; cell lines for 
discovery and screening of novel drug candidates; GMP production of healthcare 
products; companion animal and livestock health; production of industrial 
materials such as enzymes, biofuels and chemicals; and synthetic biology.

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo 
Corporation, serves as the exclusive agent for ERS Genomics in Japan.

Photo -
Logo -

Source: ERS Genomics